Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Boyoglu-Barnum S, Gaston KA, Todd SO, Boyoglu C, Chirkova T, Barnum TR, Jorquera P, Haynes LM, Tripp RA, Moore ML, Anderson LJ.

J Virol. 2013 Oct;87(20):10955-67. doi: 10.1128/JVI.01164-13. Epub 2013 Jul 24.

2.

Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Boyoglu-Barnum S, Chirkova T, Todd SO, Barnum TR, Gaston KA, Jorquera P, Haynes LM, Tripp RA, Moore ML, Anderson LJ.

J Virol. 2014 Sep;88(18):10569-83. doi: 10.1128/JVI.01503-14. Epub 2014 Jul 2.

3.
4.

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Boyoglu-Barnum S, Todd SO, Meng J, Barnum TR, Chirkova T, Haynes LM, Jadhao SJ, Tripp RA, Oomens AG, Moore ML, Anderson LJ.

J Virol. 2017 Apr 28;91(10). pii: e02059-16. doi: 10.1128/JVI.02059-16. Print 2017 May 15.

5.

An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice.

Boyoglu-Barnum S, Todd SO, Chirkova T, Barnum TR, Gaston KA, Haynes LM, Tripp RA, Moore ML, Anderson LJ.

Virology. 2015 Sep;483:117-25. doi: 10.1016/j.virol.2015.02.035. Epub 2015 May 15.

6.

Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice.

Miao C, Radu GU, Caidi H, Tripp RA, Anderson LJ, Haynes LM.

J Gen Virol. 2009 May;90(Pt 5):1119-23. doi: 10.1099/vir.0.009308-0. Epub 2009 Mar 4.

8.

The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection.

Stokes KL, Currier MG, Sakamoto K, Lee S, Collins PL, Plemper RK, Moore ML.

J Virol. 2013 Sep;87(18):10070-82. doi: 10.1128/JVI.01347-13. Epub 2013 Jul 10.

9.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.

J Virol. 2017 Jul 12;91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.

PMID:
28539438
10.

Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Han J, Takeda K, Wang M, Zeng W, Jia Y, Shiraishi Y, Okamoto M, Dakhama A, Gelfand EW.

Am J Respir Cell Mol Biol. 2014 Jul;51(1):143-54. doi: 10.1165/rcmb.2013-0360OC.

11.

Building a better neonatal mouse model to understand infant respiratory syncytial virus disease.

You D, Siefker DT, Shrestha B, Saravia J, Cormier SA.

Respir Res. 2015 Aug 1;16:91. doi: 10.1186/s12931-015-0244-0.

12.
13.

Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.

Caidi H, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM.

PLoS One. 2012;7(12):e51485. doi: 10.1371/journal.pone.0051485. Epub 2012 Dec 27.

14.

Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice.

Crowe JE Jr, Murphy BR, Chanock RM, Williamson RA, Barbas CF 3rd, Burton DR.

Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1386-90.

15.

Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.

Haynes LM, Caidi H, Radu GU, Miao C, Harcourt JL, Tripp RA, Anderson LJ.

J Infect Dis. 2009 Aug 1;200(3):439-47. doi: 10.1086/600108.

PMID:
19545210
16.

Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis.

Hotard AL, Lee S, Currier MG, Crowe JE Jr, Sakamoto K, Newcomb DC, Peebles RS Jr, Plemper RK, Moore ML.

J Virol. 2015 Jan;89(1):512-22. doi: 10.1128/JVI.02472-14. Epub 2014 Oct 22.

17.

Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.

Bian C, Liu S, Liu N, Zhang G, Xing L, Song Y, Duan Y, Gu H, Zhou Y, Zhang P, Li Z, Zhang K, Wang Z, Zhang S, Wang X, Yang P.

Antiviral Res. 2014 Apr;104:110-7. doi: 10.1016/j.antiviral.2014.01.022. Epub 2014 Feb 6.

PMID:
24509239
18.

A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.

Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS Jr.

J Virol. 2009 May;83(9):4185-94. doi: 10.1128/JVI.01853-08. Epub 2009 Feb 11.

19.

Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody.

Huang K, Wu H.

Microbiol Spectr. 2014 Aug;2(4):AID-0014-2014. doi: 10.1128/microbiolspec.AID-0014-2014. Review.

PMID:
26104207
20.

Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.

Widjojoatmodjo MN, Bogaert L, Meek B, Zahn R, Vellinga J, Custers J, Serroyen J, Radošević K, Schuitemaker H.

Vaccine. 2015 Oct 5;33(41):5406-14. doi: 10.1016/j.vaccine.2015.08.056. Epub 2015 Aug 28.

Supplemental Content

Support Center